financetom
OESX
financetom
/
Industrials
/
OESX
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Orion Energy Systems, Inc.OESX
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Orion Energy Systems, Inc. researches, designs, develops, manufactures, markets, sells, installs, and implements energy management systems for commercial office and retail, exterior area lighting, and industrial applications in North America.

The company operates through three segments: Orion Services Group, Orion Distribution Services, and Orion U.S. Markets.

It also offers interior light emitting diode (LED) high bay fixtures; smart building control systems, which provide lighting control options and data intelligence capabilities for building managers; and LED troffer door retrofit for use in office or retail grid ceilings.

In addition, the company provides various other LED and HIF fixtures for lighting and energy management needs comprising fixtures for agribusinesses, parking lots, roadways, retail, mezzanine, outdoor applications, and private label resale.

Further, it provides maintenance, repair, and replacement services; offers lighting-related energy management services, such as site assessment, site field verification, utility incentive and government subsidy management, engineering design, project management, installation, facility design commissioning, and recycling; and sells and distributes replacement lamps and fixture components into the after-market.

The company serves customers directly and through independent sales agencies and distributors, national account end-users, federal and state government facilities, regional account end-users, electrical distributors, electrical contractors, and energy service companies.

Orion Energy Systems, Inc. was incorporated in 1996 and is headquartered in Manitowoc, Wisconsin.

Latest News >
Guardant Health Shares Halted; FDA Panel to Review Premarket Application of Colorectal Cancer Screening Test
Guardant Health Shares Halted; FDA Panel to Review Premarket Application of Colorectal Cancer Screening Test
May 23, 2024
07:57 AM EDT, 05/23/2024 (MT Newswires) -- Guardant Health ( GH ) shares were temporarily halted on Thursday as a Food and Drug Administration panel prepared to meet to review the premarket approval application for the company's Shield blood test to screen for colorectal cancer. Advisory committees provide independent expert advice and non-binding recommendations to the FDA, the company said....
Update: Market Chatter: Google Chooses State in Southern India for Smartphone Production
Update: Market Chatter: Google Chooses State in Southern India for Smartphone Production
May 23, 2024
07:57 AM EDT, 05/23/2024 (MT Newswires) -- (Updates with additional details.) Alphabet's (GOOG) Google ( GOOG ) is planning to invest billions of dollars in India's southern state of Tamil Nadu to set up production of its Pixel phones, Bloomberg reported Thursday, citing unnamed people familiar with the matter. Tamil Nadu's Minister for Industries T.R.B. Rajaa and other senior officials...
Market Chatter: Goldman Sachs Gets First-Ever Saudi HQ License for Wall Street Bank
Market Chatter: Goldman Sachs Gets First-Ever Saudi HQ License for Wall Street Bank
May 23, 2024
07:56 AM EDT, 05/23/2024 (MT Newswires) -- Goldman Sachs Group ( GS ) became the first Wall Street bank to receive a license from Saudi Arabia to set up its regional headquarters in Riyadh, Bloomberg reported Thursday, citing people familiar with the matter. Under state contract rules issued in 2021 that went into effect this year, firms must have a...
Tango Therapeutics Discontinues TNG348 Program After Showing Liver Toxicity in Trials; Shares Tumble Premarket
Tango Therapeutics Discontinues TNG348 Program After Showing Liver Toxicity in Trials; Shares Tumble Premarket
May 23, 2024
07:55 AM EDT, 05/23/2024 (MT Newswires) -- Tango Therapeutics ( TNGX ) said Thursday it will discontinue developing its TNG348 program due to liver toxicity experienced by patients during clinical trials. Patients remaining in the study for more than eight weeks exhibited liver function abnormalities, leading to the decision to terminate the program, Tango said. TNG348 was being developed as...
Copyright 2023-2025 - www.financetom.com All Rights Reserved